Aardvark Therapeutics (AARD) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Aardvark Therapeutics is the larger company by market cap ($97.4 million vs $89.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | AARD | RTSN |
|---|---|---|
| Share price | $4.45 | $11.32 |
| Market cap | $97.39M | $89.22M |
| 1-day change | -6.51% | +7.50% |
| YTD return | -63.73% | — |
| 1-year return | -67.46% | — |
| EPS (TTM) | $-3.21 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.60 | $11.79 |
| 52-week low | $3.35 | $9.66 |
| Distance from 52-week high | -73.19% | -3.99% |
| Analyst consensus | buy | — |
| Avg. price target upside | +149.66% | — |
| Average volume | 146.39K | 789.20K |
| Shares outstanding | 21.88M | 7.88M |
| Employees | 28 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
AARD vs RTSN FAQ
Which is bigger, Aardvark Therapeutics or Retension Pharmaceuticals?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $97.39M compared with $89.22M for Retension Pharmaceuticals (RTSN).
Are Aardvark Therapeutics and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.